Streetbeat News

Products Services

SLS

SELLAS Life Sciences Group has announced initial topline Phase 2a data for SLS009 in Acute Myeloid Leukemia (AML). SLS009 is the first CDK9 inhibitor in combination with AZA/VEN to achieve a complete response in an AML patient resistant to Venetoclax combination therapies. The first patient enrolled achieved CR and is in the fifth month of treatment. Four patients continue on treatment and all patients are alive. Anti-leukemic effects were observed in all patients and no significant safety issues were observed.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:46 pm

APRE

Aprea Therapeutics, Inc. (NASDAQ:APRE) presented initial clinical data on ATRN-119 and pre-clinical data on ATRN-1051 at the AACR-NCI-EORTC International Conference. The data includes first-in-human clinical data from the ongoing Phase 1 dose escalation trial of ATRN-119, and pre-clinical data from the WEE1 inhibitor, ATRN-1051. The company plans to submit an IND for ATRN-1051 in Q4 2023. ATRN-119 is in an ongoing Phase 1/2a dose escalation trial in solid tumors, with no hematologic or liver function toxicities observed so far. The company anticipates dose expansion of the trial in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:45 pm

AAPL

BTCUSD

ETHUSD

NFLX

PFE

SCHW

SPY

TSLA

This week, Tesla and Netflix are in the earnings spotlight, with analysts divided on Q3 reporting season. Pfizer, Charles Schwab, and three other stocks are also on investors' radar. In crypto news, Dogecoin's path to $1 is being watched closely, while Shiba Inu's burn rate has increased by 270%. Apple is rumored to be launching new iPads this week. Tesla CEO Elon Musk has been boasting about the company's Full Self-Driving technology, and a job posting suggests Tesla may be expanding into South America.

Portfolio Pulse from Akanksha Bakshi

October 16, 2023 | 12:41 pm

CJET

Chijet Motor Company, Inc. (NASDAQ:CJET) has successfully expanded its new energy vehicle (NEV) offerings into rural areas, leveraging Chinese government policies promoting NEV adoption. The company's products have gained significant traction among rural consumers due to their quality, cost-effectiveness, and versatility. Chijet Motor's marketing initiatives have included group car viewings, live vehicle displays, product promotion, feature explanations, and test drives. The company views this rural expansion as a crucial strategy for broadening its sales channels and fueling its growth.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:38 pm

MLTX

MoonLake Immunotherapeutics announced 24-week top-line results from its global Phase 2 MIRA trial for maintenance treatment with its Nanobody sonelokimab. The company's shares are trading higher following the announcement.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:38 pm

TXT

Textron Aviation, a subsidiary of Textron Inc. (NYSE:TXT), has announced the introduction of a new Cessna Citation business jet, the Cessna Citation CJ3 Gen2. The new jet, which is expected to enter service in 2025, features enhancements in the cockpit and cabin, and is designed to operate using Sustainable Aviation Fuel (SAF). The company is already taking orders for the new jet.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:37 pm

PFE

Pfizer's research and development in oncology will not be affected by the company's cost-cutting program. The company is also starting negotiations with payers on U.S. commercial prices for its Covid treatment, Paxlovid.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:35 pm

CRL

Charles River Laboratories International, Inc. (NYSE:CRL) has announced its ability to conduct preclinical cancer research using ITCC-P4's collection of 400 annotated pediatric cancer models. This comes as regulatory guidelines necessitate testing for pediatric indications in oncology research and development. Charles River is offering clients access to this collection, which is critical for research due to the FDA's RACE for Children Act requiring all oncology drugs to be tested for pediatric indications before approval.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:34 pm

PHUN

VHC Health has renewed its Digital Front Door application with Phunware for another five years. The terms of the agreement were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:33 pm

ACRV

Acrivon Therapeutics (NASDAQ:ACRV) presented data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, demonstrating the capabilities of its AP3 platform and ACR-368 OncoSignature assay for patient responder identification. The data supports the use of the ACR-368 OncoSignature assay in ongoing Phase 2 clinical trials for patients with ovarian, endometrial, or bladder cancer. The company's AP3 platform is designed to measure the activity state of drug-regulated proteins and drug-induced resistance mechanisms to match with drug mechanism-of-action.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:33 pm